Integrin ανβ3 is a receptor and is highly expressed on activated and proliferating endothelial cells during the growth and metastasis of solid tumors but not on resting endothelial cells and normal organs. Because RGD peptide binds to integrin ανβ3 receptor, a variety of radiolabeled RGD peptides have been evaluated for non-invasive imaging of integrin ανβ3-positive tumors.
In an attempt to develop RGD-based radiopharmaceuticals, a novel GluDTPA-cyclo arginine-glycine-aspartic acid-d-phenylalanine-lysine (GluDTPA-cycloRGDfK) was simply synthesized and radiolabeled with 177Lu. Also, tumor targeting and retention of the radiolabeled complex were evaluated in U87MG glioma-bearing mice.
The 177Lu-labeled GluDTPA-cyclo(RGDfK) was formulated with a high radiolabeling yield (>98%) under mild condition, and the radiochemical purity was sustained in both saline and serum for over 4 days at 37°C. The radiolabeled compounds were rapidly cleared from the blood pool and non-target tissue. Tumor-to-blood ratio was 12.09 at 2 h post injection and increased to 134.67 at 24 h, while tumor to liver ratio was 2.01 at 24 h similar to that of 2 h.
Though it is inappropriate for targeted therapy due to its low uptake in tumor (~ 1 %ID/g), the acceptable results on radiochemistry and biodistribution propose to take a further assessment for non-invasive imaging and detection of integrin ανβ3-positive tumors by applying diagnostic radionuclides. Copyright © 2011 John Wiley & Sons, Ltd.